Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Springer
    European journal of clinical microbiology & infectious diseases 18 (1999), S. 399-402 
    ISSN: 1435-4373
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The objective of this study was to investigate the spectrum and frequency of rare AIDS-defining diseases in the Swiss HIV Cohort Study. AIDS-defining diseases contributing less than 1% to the absolute number of all recorded AIDS-defining diseases in at least one of five periods (1988–1990, 1991–1992, 1993–1994, 1995–1996, 1997) were defined as being rare. A total of 9110 HIV-infected subjects were included in this study. Over the entire 9-year period, the following rare diseases were diagnosed: progressive multifocal leukoencephalopathy (n=138), disseminated cryptococcosis (n=67), visceral herpes simplex disease (n=66), primary cerebral lymphoma (n=65), indeterminate cerebral lesion (n=50), cryptococcal meningitis (n=34), Mycobacterium kansasii disease (n=32), recurrent Salmonella septicemia (n=22), intestinal isosporiasis (n=21), candidiasis of the trachea, bronchi and lungs (n=19), toxoplasma retinitis (n=16), disseminated toxoplasmosis (n=8), invasive cervical carcinoma (n=8), extrapulmonary Pneumocystis disease (n=5), disseminated histoplasmosis (n=1) and disseminated coccidioidomycosis (n=1). Rare diseases accounted for 7.3% of all AIDS-defining diseases over the entire 9-year period. Physicians should be aware of the likelihood of a broad spectrum of AIDS-defining diseases in HIV-infected patients.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1619-7089
    Keywords: Key words: Somatostatin receptor-mediated internal radiotherapy ; DTPA-d-Phe1-octreotide (OctreoScan) ; DOTA-d-Phe1-Tyr3-octreotide (DOTATOC) ; Indium-111 ; Yttrium-90
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract. This study presents the first successful use of a peptidic vector, DOTATOC, labelled with the β-emitting radioisotope yttrium-90, for the treatment of a patient with somatostatin receptor-positive abdominal metastases of a neuroendocrine carcinoma of unknown localization. Tumour response and symptomatic relief were achieved. In addition, the new substance DOTATOC was labelled with the diagnostic chemical analogue indium-111 and studied in three patients with histopathologically verified neuroendocrine abdominal tumours for its diagnostic sensitivity and compared with the commercially available OctreoScan. In all patients the kidney-to-tumour uptake ratio (in counts per pixel) was on average 1.9-fold lower with 111In-DOTATOC than with OctreoScan. DOTATOC could be a potential new diagnostic and therapeutic agent in the management of neuroendocrine tumours.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    ISSN: 1619-7089
    Keywords: Somatostatin receptor-mediated internal radiotherapy ; DTPA-d-Phe1-octreotide (OctreoScan) ; DOTA-d-Phe1-Tyr3-octreotide (DOTATOC) ; Indium-111 ; Yttrium-90
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract This study presents the first successful use of a peptidic vector, DOTATOC, labelled with the β-emitting radioisotope yttrium-90, for the treatment of a patient with somatostatin receptor-positive abdominal metastases of a neuroendocrine carcinoma of unknown localization. Tumour response and symptomatic relief were achieved. In addition, the new substance DOTA-TOC was labelled with the diagnostic chemical analogue indium-111 and studied in three patients with histopathologically verified neuroendocrine abdominal tumours for its diagnostic sensitivity and compared with the commercially available OctreoScan. In all patients the kidney-to-tumour uptake ratio (in counts per pixel) was on average 1.9-fold lower with111In-DOTATOC than with OctreoScan. DOTATOC could be a potential new diagnostic and therapeutic agent in the management of neuroendocrine tumours.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...